Hot Features
Premium
Register to chat with like-minded investors on our interactive forums.
LEIPURIN PLC APPLIES FOR LISTING ON THE NASDAQ OMX HELSINKI LTD
The Board of Directors of Leipurin, and the Board of Directors of its sole shareholder Aspo, have decided on 19 November 2014 to apply for listing of the shares in Leipurin on the Official List of NASDAQ OMX Helsinki Ltd as previously announced. Leipurin and Aspo will separately announce about the share issue and the share sale related to the listing. The subscription price range of the shares offered for subscription in the Offering is preliminarily EUR 2.10 – 2.60 per share.
The maximum amount of new shares of the Company to be issued in the Offering is 2,128,000 shares and the maximum amount of shares of the Company to be sold is 11,313,000 shares. Trading in Leipurin’s shares on the Prelist of the Helsinki Stock Exchange is expected to commence on or about 9 December 2014 and on the Official List on or about 11 December 2014.
The Company has submitted a prospectus related to the Offering and the planned distribution of dividends as shares of Leipurin to be approved by the Finnish Financial Supervisory Authority. The prospectus is expected to be approved on or about 20 November 2014. The subscription period for the Offering will commence on or about 24 November 2014 at 9.30 a.m. (Finnish time) and end at the latest on 5 December 2014 at 4.30 p.m. (Finnish time).
Leipurin will submit a listing application to Helsinki Stock Exchange to list the shares of the Company.
The Board of Directors of Aspo proposes to the Extraordinary Shareholders’ Meeting of Aspo to be held on 11 December 2014 that the Board of Directors of Aspo shall be authorised to distribute dividend a maximum amount of EUR 0.25 per share to its shareholders, either to be distributed in shares in Leipurin, in cash or as a combination of them.
Pohjola Bank Plc acts as the Lead Manager of the Offering. Attorneys at law Borenius Ltd acts as the legal advisor of the Offering. Ernst & Young Oy acts as the auditor of Aspo and Leipurin.
